Help | Scores |Exit
Fragmin | Magnex | Solu Medrol
Lisinopril Drug Name:  
A|B|C|D|E|F|G|H|I|K|L|M|N|O|P|Q|R|S|T|V|Z
Indications
Dosages
Interactions
Precautions
Contraindications
Adverse Reactions
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interactions:

Allopurinol

  • Adverse Effect hypersensitivity reactions (Stevens-Johnson syndrome, skin eruptions)
  • Clinical Management If these drugs are used concurrently, monitor for hypersensitivity reactions.

    Amiloride

  • Adverse Effect hyperkalemia
  • Clinical Management Although such increases are usually transient, monitor serum potassium levels for persistent elevations in patients on this combination, especially in patients with renal dysfunction or diabetes and the elderly. Severe arrhythmias and death have been reported from hyperkalemia with such combinations.

    Aspirin

  • Adverse Effect decreased captopril effectiveness
  • Clinical Management Although studies have suggested an interaction between Lisinopril and aspirin, the clinician should weigh the benefits against the risks of combining these two agents.

    Bumetanide

  • Adverse Effect postural hypotension (first dose)
  • Clinical Management Start with a very low dose of the angiotensin converting enzyme (ACE) inhibitor in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Celecoxib

  • Adverse Effect Decreased antihypertensive and natriuretic effects
  • Clinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Chlorthalidone

  • Adverse Effect postural hypotension (first dose)
  • Clinical Management Start with a very low dose of Lisinopril in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Clopamide

  • Adverse Effect postural hypotension (first dose)
  • Clinical Management Start with a very low dose of Lisinopril in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Diclofenac Preps.

  • Adverse Effect Decreased antihypertensive and natriuretic effects
  • Clinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Erythropoietin

  • Adverse Effect higher maintenance doses of erythropoietin to maintain the target hematocrit
  • Clinical Management Monitor patients receiving Lisinopril for erythropoietin efficacy. When given concomitantly, doses of erythropoietin may be higher than expected.

    Flurbiprofen

  • Adverse Effect Decreased antihypertensive and natriuretic effects
  • Clinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Frusemide

  • Adverse Effect postural hypotension (first dose)
  • Clinical Management Start with a very low dose of the angiotensin converting enzyme (ACE) inhibitor in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Ibuprofen

  • Adverse Effect Decreased antihypertensive and natriuretic effects
  • Clinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Indapamide

  • Adverse Effect postural hypotension (first dose)
  • Clinical Management Start with a very low dose of the angiotensin converting enzyme (ACE) inhibitor in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Indomethacin

  • Adverse Effect Decreased antihypertensive and natriuretic effects
  • Clinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Ketoprofen

  • Adverse Effect Decreased antihypertensive and natriuretic effects
  • Clinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Ketorolac

  • Adverse Effect Decreased antihypertensive and natriuretic effects
  • Clinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Lithium

  • Adverse Effect Lithium toxicity (weakness, tremor, excessive thirst, confusion) and/or nephrotoxicity
  • Clinical Management The combination of lithium and Lisinopril should be avoided if possible, though the choice of an alternative antihypertensive agent that does not interact with lithium is limited. If lithium and lisinopril are used concurrently, serum lithium levels should be closely monitored and the patient followed for any symptoms of lithium toxicity.

    Mefenamic Acid

  • Adverse Effect Decreased antihypertensive and natriuretic effects
  • Clinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Meloxicam

  • Adverse Effect Decreased antihypertensive and natriuretic effects
  • Clinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Nabumetone

  • Adverse Effect Decreased antihypertensive and natriuretic effects
  • Clinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Naproxen

  • Adverse Effect Decreased antihypertensive and natriuretic effects
  • Clinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Nimesulide

  • Adverse Effect Decreased antihypertensive and natriuretic effects
  • Clinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Oxyphenbutazone

  • Adverse Effect Decreased antihypertensive and natriuretic effects
  • Clinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Paracetamol

  • Adverse Effect Decreased antihypertensive and natriuretic effects
  • Clinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Phenacetin

  • Adverse Effect Decreased antihypertensive and natriuretic effects
  • Clinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Phenylbutazone

  • Adverse Effect Decreased antihypertensive and natriuretic effects
  • Clinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Piroxicam

  • Adverse Effect Decreased antihypertensive and natriuretic effects
  • Clinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Spironolactone

  • Adverse Effect hyperkalemia
  • Clinical Management Although such increases are usually transient, monitor serum potassium levels for persistent elevations in patients on this combination, especially in patients with renal dysfunction or diabetes and the elderly. Severe arrhythmias and death have been reported from hyperkalemia with such combinations.

    Tenoxicam

  • Adverse Effect Decreased antihypertensive and natriuretic effects
  • Clinical Management Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Xipamide

  • Adverse Effect postural hypotension (first dose)
  • Clinical Management Start with a very low dose of the angiotensin converting enzyme (ACE) inhibitor in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.
  • Lactulose
    Lamotrigine
    Levofloxacin Ophthalmic Solution
    Levothyroxine Sodium
    Lidocaine (Lignocaine)
    Liothyronine Sodium
    Lithium Carbonate
    Loperamide Hydrochloride
    Loratadine
    Lorazepam
    LMWH sodsalt
    Labetalol
    Lacidipine
    Lactobacillus
    L - asparaginase
    L-ornithine l-aspartate
    Lactobacillus Sporogenes - VU
    Lamivudine
    Lansoprazole
    Latanoprost
    Lefulnomide
    Leucoverin
    Leuprolide
    Levamisole
    Levobunolol
    Levocetrizine
    Levodopa
    Levofloxacin
    Levonorgestrel
    Lidoflazine
    Lignocaine LA
    Lincomycin
    Linezolid
    Liq Paraffin
    Lisinopril
    Lithium
    Lomefloxacin
    Lomustine
    Loperamide
    Losartan
    Lovastatin
    Loxapine
    Lynoestrenol
     
    Disclaimer